Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase EARLY_PHASE1 1Phase 1 1

Status

Unknown 3Recruiting 1Active not recruiting 1

Sponsor Class

OTHER_GOV 2OTHER 2INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 5

Conditions

Carcinoma, Non-Small-Cell Lung 6874Lung Neoplasms 5105Small Cell Lung Carcinoma 1166Breast Neoplasms 855Neoplasms 762Colorectal Neoplasms 670Melanoma 566Ovarian Neoplasms 506Neoplasm Metastasis 481Pancreatic Neoplasms 473Adenocarcinoma of Lung 398Stomach Neoplasms 396Prostatic Neoplasms 370Head and Neck Neoplasms 368Carcinoma, Renal Cell 350Esophageal Neoplasms 337Squamous Cell Carcinoma of Head and Neck 325Mesothelioma, Malignant 324Colonic Neoplasms 294Mesothelioma 289Urinary Bladder Neoplasms 262Brain Neoplasms 254Uterine Cervical Neoplasms 243Triple Negative Breast Neoplasms 223Sarcoma 198Endometrial Neoplasms 196Carcinoma, Hepatocellular 186NSCLC 167Pleural Effusion, Malignant 160Kidney Neoplasms 160

Interventions

toripalimab 1pelcitoclax 1osimertinib 1Pemetrexed 1Paclitaxel 1Injections 1Erlotinib Hydrochloride 1Docetaxel 1Cisplatin 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
EGFR Positive Non-small Cell Lung Cancer × Thoracic × Clear all
NCT07322783 2026-01-07

Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification

Qingdao Central Hospital

Phase 2 Recruiting
60 enrolled
Thoracic

EGFR Positive Non-small Cell Lung Cancer

NCT04001777 2025-10-01

A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients

Ascentage Pharma Group Inc.

Phase 1 Active not recruiting
80 enrolled
Thoracic

EGFR Positive Non-small Cell Lung Cancer

NCT06208033 2024-01-17

SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC)

Fujian Cancer Hospital

Phase EARLY_PHASE1 Unknown
40 enrolled
Thoracic

EGFR Positive Non-small Cell Lung Cancer

NCT03126799 2022-04-06

AvaTa

National Cancer Center, Korea

Phase 2 Unknown
128 enrolled
Thoracic

EGFR Positive Non-small Cell Lung Cancer

NCT03382795 2021-07-15

Retreatment With Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitor in EGFR Mutation Positive Patients

Korea University Guro Hospital

Phase 2 Unknown
63 enrolled
Thoracic

EGFR Positive Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡